Product
Fluzone Quadrivalent
Aliases
Fluzone® Quadrivalent
7 clinical trials
7 indications
Indication
InfluenzaIndication
HumanIndication
Influenza ImmunizationIndication
Healthy Control ParticipantsIndication
Adverse Reaction to ImmunizationIndication
Breast CancerIndication
Breast Cancer Triple NegativeClinical trial
A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1™ Adjuvant Against Fluzone® Quadrivalent in Clinically Stable Adults ≥ 65 Years of AgeStatus: Completed, Estimated PCD: 2020-10-29
Clinical trial
Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose Quadrivalent, Influenza Vaccines, 2021-2022 FormulationsStatus: Completed, Estimated PCD: 2021-11-10
Clinical trial
Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose Quadrivalent, Influenza Vaccines, 2020-2021 FormulationsStatus: Completed, Estimated PCD: 2020-12-18
Clinical trial
Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose, Influenza Vaccines, 2019-2020 FormulationsStatus: Completed, Estimated PCD: 2019-12-10
Clinical trial
Randomized Participant- and Investigator-Blinded Trial to Compare the Clinical Efficacy of Recombinant Influenza Vaccine to Standard Dose Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years in the United StatesStatus: Terminated, Estimated PCD: 2023-12-31
Clinical trial
Characterization of Immune Response to Intradermal Influenza VaccinationStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase I Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-31